David Grayzel

1.6k total citations
23 papers, 1.0k citations indexed

About

David Grayzel is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, David Grayzel has authored 23 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 7 papers in Oncology and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in David Grayzel's work include Heat shock proteins research (9 papers), Computational Drug Discovery Methods (5 papers) and Migraine and Headache Studies (4 papers). David Grayzel is often cited by papers focused on Heat shock proteins research (9 papers), Computational Drug Discovery Methods (5 papers) and Migraine and Headache Studies (4 papers). David Grayzel collaborates with scholars based in United States, United Kingdom and Belgium. David Grayzel's co-authors include Peter J. Goadsby, Egilius L.H. Spierings, Steven Sweeney, David W. Dodick, Lecia V. Sequist, John R. Walker, Pasi A. Jänne, Ronald B. Natale, Scott Gettinger and Jennifer Sweeney and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Lancet Neurology.

In The Last Decade

David Grayzel

23 papers receiving 994 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David Grayzel United States 12 440 366 292 226 183 23 1.0k
Tatsuya Kurihara Japan 16 927 2.1× 62 0.2× 104 0.4× 167 0.7× 160 0.9× 43 1.7k
Chantal Tallaksen Norway 29 604 1.4× 87 0.2× 142 0.5× 75 0.3× 52 0.3× 77 2.3k
Catalina Amador United States 12 285 0.6× 204 0.6× 109 0.4× 53 0.2× 70 0.4× 27 1.2k
Astrid McKeown United Kingdom 12 254 0.6× 54 0.1× 179 0.6× 658 2.9× 599 3.3× 34 1.2k
Carlo Tapparelli Switzerland 15 283 0.6× 212 0.6× 102 0.3× 38 0.2× 84 0.5× 30 844
Radoslav Matěj Czechia 18 385 0.9× 85 0.2× 45 0.2× 106 0.5× 117 0.6× 144 1.2k
R.R. Frants Netherlands 19 396 0.9× 336 0.9× 211 0.7× 34 0.2× 349 1.9× 33 1.1k
Florian Hiemeyer Germany 10 213 0.5× 271 0.7× 242 0.8× 57 0.3× 165 0.9× 38 1.3k
Archana S. Nagaraja United States 14 356 0.8× 392 1.1× 30 0.1× 156 0.7× 280 1.5× 22 1.1k
N. Braun Germany 13 185 0.4× 73 0.2× 47 0.2× 80 0.4× 55 0.3× 26 884

Countries citing papers authored by David Grayzel

Since Specialization
Citations

This map shows the geographic impact of David Grayzel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Grayzel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Grayzel more than expected).

Fields of papers citing papers by David Grayzel

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Grayzel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Grayzel. The network helps show where David Grayzel may publish in the future.

Co-authorship network of co-authors of David Grayzel

This figure shows the co-authorship network connecting the top 25 collaborators of David Grayzel. A scholar is included among the top collaborators of David Grayzel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Grayzel. David Grayzel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Monteith, David, Emily C. Collins, Corinne Vandermeulen, et al.. (2017). Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the CGRP Binding Monoclonal Antibody LY2951742 (Galcanezumab) in Healthy Volunteers. Frontiers in Pharmacology. 8. 740–740. 54 indexed citations
2.
Benschop, Robert J., Anne Van Hecken, David Monteith, et al.. (2015). Translational Pharmacodynamics of Calcitonin Gene-Related Peptide Monoclonal Antibody LY2951742 in a Capsaicin-Induced Dermal Blood Flow Model. Journal of Pharmacology and Experimental Therapeutics. 354(3). 350–357. 44 indexed citations
3.
Goadsby, Peter J., DW Dodick, Egilius L.H. Spierings, et al.. (2014). EHMTI-0178. CGRP monoclonal antibody LY2951742 for the prevention of migraine: a phase 2, randomized, double-blind, placebo-controlled study. The Journal of Headache and Pain. 15(S1). 7 indexed citations
4.
5.
Campagna, Jason, Kevin Pojasek, David Grayzel, John C.R. Randle, & Douglas E. Raines. (2014). Advancing Novel Anesthetics. Anesthesiology. 121(6). 1203–1216. 28 indexed citations
6.
Wagner, Andrew J., Rashmi Chugh, Lee S. Rosen, et al.. (2013). A Phase I Study of the HSP90 Inhibitor Retaspimycin Hydrochloride (IPI-504) in Patients with Gastrointestinal Stromal Tumors or Soft-Tissue Sarcomas. Clinical Cancer Research. 19(21). 6020–6029. 67 indexed citations
7.
Siegel, David, Sundar Jagannath, David H. Vesole, et al.. (2011). A phase 1 study of IPI-504 (retaspimycin hydrochloride) in patients with relapsed or relapsed and refractory multiple myeloma. Leukemia & lymphoma. 52(12). 2308–2315. 23 indexed citations
8.
Sequist, Lecia V., Ronald B. Natale, Neil Senzer, et al.. (2010). Association between anaplastic lymphoma kinase rearrangements (rALK) and the clinical activity of IPI-504 (retaspimycin hydrochloride), a novel Hsp90 inhibitor, in patients with non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 28(15_suppl). 7517–7517. 7 indexed citations
9.
Sequist, Lecia V., Scott Gettinger, Ronald B. Natale, et al.. (2009). A phase II trial of IPI-504 (retaspimycin hydrochloride), a novel Hsp90 inhibitor, in patients with relapsed and/or refractory stage IIIb or stage IV non-small cell lung cancer (NSCLC) stratified by EGFR mutation status. Journal of Clinical Oncology. 27(15_suppl). 8073–8073. 11 indexed citations
10.
Riely, Gregory J., Merrill J. Egorin, David B. Solit, et al.. (2009). A phase Ib trial of IPI-504 (retaspimycin hydrochloride), a novel Hsp90 inhibitor, in combination with docetaxel. Journal of Clinical Oncology. 27(15_suppl). 3547–3547. 6 indexed citations
11.
12.
Morgan, Jeffrey A., Rashmi Chugh, Lee S. Rosen, et al.. (2008). Inhibition of heat shock protein 90 (Hsp90) with the novel agent IPI-504 in metastatic GIST following failure of tyrosine kinase inhibitors (TKIs) or other sarcomas: Clinical results from phase I trial. Journal of Clinical Oncology. 26(15_suppl). 10503–10503. 43 indexed citations
13.
Sequist, Lecia V., Pasi A. Jänne, John R. Walker, et al.. (2007). Phase I/II trial of the novel Hsp90 inhibitor, IPI-504, in patients with relapsed and/or refractory stage IIIB or stage IV non-small cell lung cancer stratified by EGFR mutation status. Molecular Cancer Therapeutics. 6. 14 indexed citations
14.
Demetri, George D., Suzanne George, Jeffrey A. Morgan, et al.. (2007). Inhibition of the Heat Shock Protein 90 (Hsp90) chaperone with the novel agent IPI-504 to overcome resistance to tyrosine kinase inhibitors (TKIs) in metastatic GIST: Updated results of a phase I trial. Journal of Clinical Oncology. 25(18_suppl). 10024–10024. 21 indexed citations
15.
Peng, Cong, Yiguo Hu, Linghong Kong, et al.. (2007). Inhibition of heat shock protein 90 prolongs survival of mice with BCR-ABL-T315I–induced leukemia and suppresses leukemic stem cells. Blood. 110(2). 678–685. 117 indexed citations
16.
Abbeele, Annick D. Van den, Jeffrey T. Yap, David Grayzel, John R. Walker, & George D. Demetri. (2007). Inhibition and flare patterns of metabolic response to the heat shock protein 90 (Hsp90) inhibitor IPI-504 visualized by FDG-PET in patients (pts) with advanced gastrointestinal stromal tumors (GIST) resistant to tyrosine kinase inhibitor (TKI) therapy. Journal of Clinical Oncology. 25(18_suppl). 3530–3530. 2 indexed citations
17.
18.
Peng, Cong, Yiguo Hu, Linghong Kong, et al.. (2006). IPI-504, a Novel, Orally Active HSP90 Inhibitor, Prolongs Survival of Mice with BCR-ABL T315I CML and B-ALL.. Blood. 108(11). 2183–2183. 2 indexed citations
19.
Siegel, David S., Sundar Jagannath, Amitabha Mazumder, et al.. (2006). Update on Phase I Clinical Trial of IPI-504, a Novel, Water-Soluble Hsp90 Inhibitor, in Patients with Relapsed/Refractory Multiple Myeloma (MM).. Blood. 108(11). 3579–3579. 13 indexed citations
20.
Mitsiades, Constantine, Nicholas Mitsiades, Joseph Negri, et al.. (2004). IPI-504: A Novel hsp90 Inhibitor with In Vitro and In Vivo Anti-Tumor Activity.. Blood. 104(11). 2403–2403. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tatsuya Kurihara Breakdown of academic impact, for papers by Chantal Tallaksen Breakdown of academic impact, for papers by Catalina Amador Breakdown of academic impact, for papers by Astrid McKeown Breakdown of academic impact, for papers by Carlo Tapparelli Breakdown of academic impact, for papers by Radoslav Matěj Breakdown of academic impact, for papers by R.R. Frants Breakdown of academic impact, for papers by Florian Hiemeyer Breakdown of academic impact, for papers by Archana S. Nagaraja Breakdown of academic impact, for papers by N. Braun
Rankless by CCL
2026